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Objective: In Australian residential aged care facilities (RACFs), the use of certain classes 
of high-risk medication such as antipsychotics, potent analgesics, and sedatives is high. 
Here, we examined the prescribed medications and subsequent changes recommended by 
geriatricians during comprehensive geriatric consultations provided to residents of RACFs via 
videoconference.
Design: This is a prospective observational study.
Setting: Four RACFs in Queensland, Australia, are included.
Participants: A total of 153 residents referred by general practitioners for comprehensive 
assessment by geriatricians delivered by video-consultation.
Results: Residents’ mean (standard deviation, SD) age was 83.0 (8.1) years and 64.1% were 
female. They had multiple comorbidities (mean 6), high levels of dependency, and were pre-
scribed a mean (SD) of 9.6 (4.2) regular medications. Ninety-one percent of patients were taking 
five or more medications daily. Of total medications prescribed (n=1,469), geriatricians recom-
mended withdrawal of 9.8% (n=145) and dose alteration of 3.5% (n=51). New medications were 
initiated in 47.7% (n=73) patients. Of the 10.3% (n=151) medications considered as high risk, 
17.2% were stopped and dose altered in 2.6%.
Conclusion: There was a moderate prevalence of potentially inappropriate high-risk medica-
tions. However, geriatricians made relatively few changes, suggesting either that, on balance, 
prescription of these medications was appropriate or, because of other factors, there was a 
reluctance to adjust medications. A structured medication review using an algorithm for with-
drawing medications of high disutility might help optimize medications in frail patients. Further 
research, including a broader survey, is required to understand these dynamics.
Keywords: frail older, geriatrician intervention, high-risk medications, residential aged care 
facilities
Introduction
Many frail older people spend their final years of life in aged care facilities. In Aus-
tralia, the proportion of older people living in care accommodation increases with age 
from 2% of people aged 65–74 years to 6% of people aged 75–84 years and 26% of 
people aged 85 years and over.1 Those living in care homes often take more medica-
tions than noninstitutionalized elderly, and the risk of morbidity as a result of medi-
cation is high.2 Also, the incidence of adverse drug events increases with the number 
of medications prescribed.3 Residential aged care facilities (RACFs) in Australia are 
institutions in which prescribing of high-risk medication such as antipsychotics, potent 
analgesics, and sedatives is high, with between 25% and 30% of patients receiving 
such medication.4–6 Ensuring high-quality care and appropriate medication use for 
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these residents is challenging given their frailty, complex 
disabilities, and multiple chronic conditions.7
Despite the growing body of literature indicating that 
medication errors and potentially inappropriate medications 
are important causes of morbidity and mortality, evidence 
for effective interventions and strategies to improve the 
pharmacological management of patients is still limited.8 
Well-organized approaches are needed to provide special-
ist advice in nursing homes to ensure quality medical care. 
Practice models that include a pharmacist as part of the 
multidisciplinary team represent best practice in inpatient, 
ambulatory, and community settings, and in care transitions 
between settings.9 Geriatrician-led case conference reviews 
and comprehensive geriatric assessments (CGAs) have been 
shown to be effective in reducing potentially inappropriate 
medications use and improved suboptimal prescribing.7,10 
Although access to geriatric services in Australian RACFs 
is limited, expert advice is increasingly provided by video-
conferencing (VC).
In the model offered in relation to this study, a special-
ist geriatrician provides a comprehensive assessment of the 
patient and input into care plans via VC. Geriatricians make 
recommendation about patients’ medications, perhaps advis-
ing that some medications are stopped or others commenced. 
We designed this study to examine whether VC-mediated 
geriatric assessment resulted in changes to medications 
prescribed, and reduced the prevalence of potentially inap-
propriate medication use.
Methods
study population and setting
We conducted a prospective observational cohort study of 
four RACFs in Queensland, Australia, that currently have 
regular access to geriatric consultations via VC. The par-
ticipating facilities were the first four to be supported by the 
geriatrician service operating out of the Centre for Research 
in Geriatric Medicine. We were able to record the informa-
tion for 153 patients assessed by four geriatricians over the 
research timeframe.
Data collection
At participating facilities, geriatrician-supported CGA is 
encouraged within 4–12 weeks of admission. All residents are 
offered CGA at entry into the participating RACF. However, 
uptake is determined by referral from the treating general 
practitioners. The CGA is conducted using a structured 
protocol based on the interRAI (Resident Assessment Instru-
ment) Long-Term Facility assessment system, administered 
by a senior registered nurse. The assessment includes a 
comprehensive diagnosis list, justification of all medica-
tions documented, functional profile, cognitive assessment 
confirming the presence or absence of cognitive and mood 
disorders, recommendations for prevention and management, 
and advanced care planning. Observations made by the nurse 
are entered into a clinical decision support system, which 
generates a draft resident health care profile and care plan. 
The clinical decision support system is mounted on a web-
based platform to permit review and comment by a specialist 
geriatrician. interRAI is a not-for-profit research consortium 
with international collaboration from more than 30 countries 
that aims to improve the quality of life of vulnerable persons 
through a unified comprehensive assessment system.
Ideally, 1–4 weeks following admission to the facility, 
residents who have been referred to a geriatrician by the GP are 
assessed via video-consultation by the specialist. The geriatrician 
is able to speak with the resident as well as attending RACF staff 
and resident’s family members if present. Recommendations to 
the GP and RACF are made, as necessary, regarding the resi-
dent’s care plan following the consultation. CGA is also offered 
to existing residents on an “as needs” basis. A formal functional 
profile is prepared, and a report is generated recording the 
recommendations made by the geriatrician. Data for this study 
were retrieved from these sources over an 18-month period from 
January 2013 to August 2014. Ethics approval was obtained 
from the University of Queensland Medical Research Ethics 
Committee. All patients or their substitute decision-maker gave 
informed consent for participation.
Key measures
The primary outcome measure was the appropriateness of 
prescribing. A high-risk medications list was created based 
on those recognized by the American Geriatric Society 2012 
Beers Criteria,11 the McLeod criteria,12 the Laroche criteria,13 
the PRISCUS criteria,14 and the Norwegian General Practice 
criteria15 (Table 1). These criteria consider a medication as 
high risk when it has a tendency to cause adverse drug events 
and drug toxicity in older adults due to its pharmacological 
properties and the physiologic changes of aging. For our 
study, we defined high-risk medications as those that are 
listed on any one of these criteria. We excluded medica-
tions not available in Australia. Polypharmacy status was 
categorized into three groups based on the number of medi-
cations prescribed: non-polypharmacy (0–4 medications), 
polypharmacy (5–9 medications), and hyper-polypharmacy 
(10 medications).16 Complementary and as-required medi-
cations were excluded. Three levels of change on current 
Clinical Interventions in Aging 2015:10 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
1045
geriatrician intervention in aged care facilities
Table 1 high-risk medications list
Medication ATC 
codes
Main concerns References
Analgesics, anti-inflammatory
NSAID
Aspirin 325 mg/day n02BA01 –  Very high risk of gastrointestinal hemorrhage, ulceration, or 
perforation, which may be fatal
11
Diclofenac M01AB05 –  risk of renal toxicity especially in patients with preexisting chronic 
kidney disease
11
Ketoprofen M01Ae03 11,14
Ketorolac M01AB15 11,12
Mefenamic acid M01Ag01 –   Risk of fluid retention and fluid overload leading to decompensated 
heart failure in patients with underlying cardiac dysfunction
11,12
Meloxicam M01AC06 11,14
naproxen M01Ae02 11
Piroxicam M01AC01 –  Indomethacin may also have Cns side effects 11,12,14
Indomethacin M01AB01 11–14
etoricoxib M01Ah05 14
Ibuprofen M01Ae01 11
Opioid analgesics
Pethidine n02AB02 –  elevated risk of delirium and falls
–  risk of neurotoxicity
11,12,14
Antiarrhythmic
Amiodarone C01BD01 –  Predisposition to bradycardia and heart block 11
Flecainide C01BC04 –  Pro-arrhythmic effects 11,14
sotalol C07AA07 –  Pro-arrhythmic effects 11,14,15
Disopyramide C01BA03 –  Potent negative inotropic effects predisposing to heart failure
–  Anticholinergic activity
11–13
Digoxin 0.125 mg/day C01AA05 –   Risk of toxicity especially in presence of renal insufficiency 11,13,14
nifedipine C08CA05 –  Potential for postural hypotension
–  short-acting formulations associated with increased mortality in elderly 
patients
11,13,14
spironolactone 25 mg/day C03DA01 –  risk of hyperkalemia 11
Diltiazem C08DB01 –   Potential to promote fluid retention and exacerbate heart failure 11
Verapamil C08DA01 11
Antibiotics
nitrofurantoin J01Xe01 –  long-term use associated with pulmonary side effects, renal 
impairment, liver damage 
11,13,14
Anticholinergics
Antihistamines
Chlorpheniramine r06AB02 –  risk of anticholinergic effect: constipation, dry mouth, visual 
disturbance, bladder dysfunction
–  Clearance reduced with advanced age
–  Increased risk of confusion and sedation, impaired cognitive 
performance
11,14
Cyproheptadine r06AX02 11,13
Dexchlorpheniramine r06AB02 11,13,15
Diphenhydramine r06AA02 11,13,14
Doxylamine r06AA09 11,13,14
Promethazine r06AD02 11,13,15
Antiparkinson agents
Benztropine n04AC01 –  risk of anticholinergic side effects 
–  not recommended for prevention of extrapyramidal symptoms due to 
antipsychotics
11
Antispasmodics
Propantheline A03AB05 –  highly anticholinergic, uncertain effectiveness 11
Oxybutynin g04BD04 –  Anticholinergic side effects
–  eCg changes (prolonged QT)
11,13,14
solifenacin g04BD08 11,13,14
Tolterodine (non-sustained release) g04BD07 11,13,14
Antithrombotics
Dipyridamole (short-acting) B01AC07 –  risk of orthostatic hypotension 11–13
Warfarin B01AA03 –  Increased risk of bleeding 11,14
Prasugrel B01AC22 11,14
Ticlopidine B01AC05 11,14
(Continued)
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Table 1 (Continued)
Medication ATC 
codes
Main concerns References
Antidepressants
TCA
Amitriptyline n06AA09 –  Peripheral anticholinergic side effects (eg, constipation, dry mouth, 
orthostatic hypotension, and cardiac arrhythmia)
11–15
Clomipramine n06AA04 11,13–15
Doxepin (6 mg) n06AA12 –  Central anticholinergic side effects (drowsiness, inner unrest, 
confusion, other types of delirium)
11,13–15
Imipramine n06AA02 –  Cognitive impairment 11–14
nortriptyline n06AA10 –  Increased risk of falls 11
SSRI
Fluoxetine (daily use) n06AB03 –  Cns side effects (nausea, insomnia,  
dizziness, confusion)
–  hyponatremia
11,14,15
Paroxetine n06AB05 –  Confusion and other types of delirium
–  Cognitive impairment
11
MAO inhibitors
Tranylcypromine n06AF04 –  hypertensive crises
–  Cerebral hemorrhage
–  Malignant hyperthermia
11,14
Antiemetic drugs
Trimethobenzamide nA –  Can cause extrapyramidal adverse effects 11
Antiepileptic drugs (AEDs)
Phenobarbitone n03AA02 –  sedation
–  Paradoxical excitation
–  highly addictive
11,14
Antihypertensive agents 
Clonidine C02AC01 –  hypotension (orthostatic), bradycardia, syncope
–  Cns side effects: sedation, cognitive impairment
–  hypotension (orthostatic)
–  Bradycardia
–  sedation
11,13,14
Methyldopa C01AB01 11,13,14
Moxonidine C02AC05 13
nifedipine C08CA05 –  short-acting nifedipine associated with increased risk of myocardial 
infarction, increased mortality in elderly patients
11,13
Prazosin C02CA01 –  hypotension
–  Dry mouth
–  Urinary incontinence/impaired micturition
–  Increased risk of cerebrovascular and cardiovascular disease
11,13,14
Terazosin g04CA03 11,14
Antipsychotics (neuroleptic drugs)
First-generation (conventional) agents
Chlorpromazine n05AA01 –  Anticholinergic and extrapyramidal side effects
–  Parkinsonism
–  hypotonia
–  sedation and risk of falls
–  Increased mortality in patients with dementia
11–13,15
Fluphenazine n05AB02 11,13,14
haloperidol (2 mg) n05AD01 11,14
Promazine n05AA03 11,13
Trifluoperazine n05AB06 11
Prochlorperazine n05AB04 11,13–15
second-generation (atypical) agents
Aripiprazole n05AX12 –  Fewer extrapyramidal side effects
–  Clozapine: increased risk of agranulocytosis and myocarditis
11
Asenapine n05Ah05 11
Clozapine n05Ah02 11,13,14
Olanzapine (10 mg) n05Ah03 11,13–15
Muscle relaxants
Baclofen M03BX01 –  Cns side effects: amnesia, confusion, falls 13,14
solifenacin g04BD08 –  Anticholinergic side effects: constipation, dry mouth, Cns side effects 11,13,14
Orphenadrine n04AB02 –  More sedation and anticholinergic side effects than safer alternatives 11
(Continued)
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Table 1 (Continued)
Medication ATC 
codes
Main concerns References
Sedative and hypnotics
long-acting benzodiazepines
Clonazepam n03Ae01 In general, all benzodiazepines increase the risk of cognitive impairment, 
delirium, falls (muscle-relaxing effect, prolonged sedation) with risk of 
hip fracture, depression, psychiatric reactions (can cause paradoxical 
reactions, eg, agitation, irritability, hallucinations, and psychosis) and 
motor vehicle accidents in older adults
11
Diazepam n05BA01 11–15
Bromazepam n05BA08 13,14
Clobazam n05BA09 13
nitrazepam n05CD02 13–15
Flunitrazepam n05CD03 13–15
short- and intermediate-acting benzodiazepines
Alprazolam n05BA12 11,13,14
lorazepam n05BA06 11,13,14
Oxazepam n05BA04 11,13–15
Temazepam n05CD07 11,13,14
Triazolam n05CD05 11–14
non-benzodiazepine hypnotics 11–14
Zolpidem n05CF02 11,13,14
Zopiclone n05CF01 13–15
Chloral hydrate n05CC01 11,14
Others
Theophylline r03DA02 –  risk of arrhythmias
–   No proof of efficacy in COPD
11,15
glipizide A10BB07 –  long half-life leading to possible prolonged hypoglycemia 13
Cimetidine A02BA01 –  Confusion
–  More interactions than other h2 antagonists
11–13
Diphenoxylate A07DA01 –   No proof of efficacy
–  Blocks the muscarinic receptors
12,13
Abbreviations: ATC, anatomical therapeutic chemical; COPD, chronic obstructive pulmonary disease; Cns, central nervous system; eCg, electrocardiogram; MAO, 
monoamine oxidase; NSAID, non-steroidal anti-inflammatory drugs; SSRI, selective serotonin reuptake inhibitors; TCA, tricyclic antidepressants.
prescription were defined as drug stopped, dose altered, and 
new drug started.
statistical analysis
The Statistical Package for Social Science 21.0 (IBM SPSS 
Statistics 21. Ink) was used for statistical analysis. Categorical 
variables were summarized using proportions and continuous 
variables using mean, standard deviation (SD), and range. 
In univariate analysis, the differences in the distribution of 
variables between patients with or without high-risk medica-
tions were compared using the chi-squared test for categorical 
variables, and nonparametric or parametric comparison of 
means for continuous variables, depending on the distribu-
tion of the data. Tests of significance were two-tailed, using 
a significance level of P0.05.
Results
Over the course of the study, 153 patients were assessed 
by the four participating geriatricians across four facilities. 
Demographics and clinical characteristics of the study popu-
lation are presented in Table 2. The mean (± SD) patient age 
was 83.0 (±8.1) years and 64.1% were female. The median 
length of stay in the facility at the time of assessment was 
488 days (range 6–3,213 days). Twenty-four percent of 
patients were assessed within 12 weeks of admission to the 
facility. Patients had multiple comorbidities (mean 6), includ-
ing dementia diagnosed in 67.3%, depression in 46.4%, and 
delirium in 11.7%. Other prevalent comorbidities were hyper-
tension (35.9%), diabetes (20.9%), heart diseases (13.7%), 
and respiratory diseases (11.1%). Patients were prescribed 
a mean (± SD) of 9.6 (±4.2) regular medications. Polyphar-
macy (5 medications) was seen in 91% (n=139) residents, 
half of whom (n=69) were exposed to hyper-polypharmacy 
(10 medications).
Of all medications prescribed (n=1,469), the geriatrician 
recommended withdrawal of 9.8% (n=145) and dose 
alteration for 3.5% (n=51) medications. Medications 
were stopped because of adverse effects (n=66), no clear 
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Table 3 Outcomes of geriatrician intervention
Interventions No of medications Reasons
Drug stopped (145 [9.8%]) 66 Adverse effects
63 no clear indication/medication burden
16 Disease cured or quiescent
Dose altered (51 [3.5%]) 36 Dose reduced (because of adverse effects and other factors)
10 Dose increased (because of ineffective dose)
5 Changed to “as required”
new drug started (102 [6.9%]) 58 Untreated morbidity
23 Better alternative to present therapy
21 symptom relief
Notes: Total medication prescribed: 1,469; total high-risk medications prescribed: 151 (10.3%).
Table 2 Demographic and clinical characteristics of study 
population
Characteristics Total, N=153
Age, years
Mean ± sD 83.0±8.1
Median 83
Females, n (%) 98 (64.1)
length of stay at the time of assessment:  
median length of stay, days (IQr)
488 (6–3,213)
Marital status (%)
Married 50 (32.6)
Widowed 73 (47.7)
separated/divorced 19 (12.4)
never married 11 (7.1)
Comorbidities (%)
Dementia 103 (67.3)
Delirium 18 (11.7)
Depression 71 (46.4)
Under nutrition 49 (32.0)
COPD/asthma 17 (11.1)
hypertension 55 (35.9)
Diabetes 32 (20.9)
Ischemic heart disease 21 (13.7)
Prescription medications
Total number of prescribed medications 1,469
Mean ± sD 9.6±4.2
Polypharmacy categories (%)
0–4 medications (non-polypharmacy) 14 (9.2)
5–9 medications (polypharmacy) 70 (45.8)
10 medications (hyper-polypharmacy) 69 (45.1)
Abbreviations: COPD, chronic obstructive pulmonary disease; IQr, interquartile 
range; sD, standard deviation.
indication/medication burden (n=63), and disease cured 
(n=16). Similarly, the medication dose was altered because 
of adverse effects and other factors (n=36), changed to “as 
required” (n=5), and ineffective dose (n=10). New medi-
cations were initiated in 47.7% (n=73) patients (Table 3). 
High-risk medications prescribed (10.3%; n=151) and 
intervention by geriatricians are listed by drug classes in 
Table 4. At least one high-risk medication was prescribed to 
58.2% (n=89) patients. The univariate analysis showed that 
the length of stay was the only variable significantly associ-
ated with patients having at least one high-risk medication 
(Table 5). Of the high-risk medications, the geriatrician 
ceased 17.2% (n=26) medications and altered the dose in 
2.6% (n=4). High-risk medications stopped were analgesics 
(n=6), antispasmodics (n=5), sedative and hypnotics (n=5), 
antipsychotics (n=3), antiarrhythmic (n=3), antihypertensive 
(n=2), gastrointestinal medications (n=1), and antibiotics 
(n=1). The dose was altered for antiarrhythmic (n=2), anti-
depressants (n=1), and sedative and hypnotics (n=1).
Discussion
To our knowledge, this is the first study of a geriatrician inter-
vention where the medication advice for residents at long-
term residential care facilities was specifically assessed via 
video-consultation. We found moderate levels of high-risk 
medications prescribed to residents in RACFs. Geriatricians 
made relatively few changes. This suggests that either the 
prescription of these medications was appropriate or other 
factors influenced the decision not to adjust medications.
The aim of defining high-risk medication use is to focus 
on a group of medications for which there is common con-
sensus about potential inappropriateness. In principle, the 
high-risk medications prescribed to RACF residents in our 
study should not have been started or continued except under 
certain conditions; for example, amiodarone, a high-risk 
medication used in older people, is a therapy that may be 
indicated to treat supraventricular arrhythmias effectively 
in patients with heart failure;17 and benzodiazepines, that 
may increase the risk of mental decline, delirium, falls, and 
fractures in older adults, may be appropriate for treating 
seizures, certain sleep disorders, and anxiety disorders.11 
The reluctance on the part of the geriatrician in adjusting/
stopping many of these high-risk medications might sug-
gest that prescription of some of these medications was 
appropriate. It is also possible that patients’ (or primary care 
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Table 5 Univariate analysis of variables influencing the use of high-risk medications
Characteristics Patients P-value
Without high-risk  
medications (n=64)
With at least one high-risk 
medication (n=89)
socio-demographic
Age 83.55±8.5 82.67±7.8 0.513
sex (female) 44 (68.8) 54 (60.7) 0.304
Clinical
length of stay 303 (70.75–780.50) 630 (100–1,022.50) 0.044
Assessment status (within 12 weeks of admission) 18 (28.1) 19 (21.3) 0.334
Polypharmacy (4 medications) 57 (89.1) 82 (92.1) 0.516
Comorbid conditions
Delirium 7 (10.9) 11 (12.4) 0.788
Dementia 44 (68.8) 59 (66.3) 0.749
Depression 27 (42.2) 44 (49.4) 0.375
Under nutrition 24 (37.5) 25 (28.1) 0.218
Note: Values represent frequency (% of n).
Table 4 high-risk medication prescribed and geriatrician 
intervention
System/therapeutic  
category/medications
High-risk  
medications 
prescribed, N (%)
Result of  
geriatrician 
intervention
Central nervous system  
medications
80 (52.9)
Antidepressants 10 (6.6) DA – 1
Antipsychotics 21 (13.9) Ds – 3
nDs – 1
sedative and hypnotics 49 (32.4) Ds – 5
DA – 1
nDs – 2
Cardiovascular system  
medications
21 (13.9)
Antiarrhythmic 12 (7.9) Ds – 3
DA – 2
nDs – 1
Antihypertensive 9 (5.9) Ds – 2
gastrointestinal 6 (3.9) Ds – 1
Antihistamines 5 (3.3)
Antithrombotic 22 (14.5)
Antiparkinson agents 1 (0.6)
Antispasmodics 5 (3.3) Ds – 5
Analgesics 9 (5.9) Ds – 6
Antibiotics 2 (1.3) Ds – 1
Total 151 (100) DA – 4
Ds – 26
nDs – 4
Abbreviations: DA, dose altered; Ds, drug stopped; nDs, new drug started.
medical practitioners’) strong belief in their medications 
might impact on an otherwise appropriate reduction in the 
number of medications taken, but this was not specifically 
explored in our study. In addition to these patient-related 
factors, there might be some prescriber-related factors that 
hinder medication adjustment, such as involvement of several 
prescribers, the use of preventive medication, and evidence-
based medicine guidelines that often induce polypharmacy, 
uncertainties of precipitating disease relapse or drug with-
drawal syndromes, and lack of risk/benefit information for 
the frail older residents.18
Interventions for appropriate prescribing in older people 
such as education, medication reviews, computerized support 
systems, and interdisciplinary team review have a positive 
impact on prescribing.10 Yet, evidence for effective interven-
tions to improve care in residential care settings is limited. 
A study by Crotty et al suggested that case conferences help 
an outreach geriatrician team to optimize medication man-
agement.7 They describe the use of multidisciplinary case 
conference meetings to review medication in RACFs with 
significant improvement in medication appropriateness in 
the intervention group. There is conflicting evidence, how-
ever, concerning the efficacy of case conference medication 
reviews. One study using case conferencing to review the 
prescription and use of medications for community-dwelling 
older adults was unsuccessful in demonstrating the change 
in inappropriate use of medications.19 A similar study in 
residential care facilities was unsuccessful in establishing 
changes in the number of medications.20 Other approaches 
to optimize prescribing in frail older people might be the 
integration of a pharmacist in a team to make a collabora-
tive approach on the quality of prescribing. Studies from 
inpatient settings suggest that the addition of a pharmacist 
to health care teams could lead to major reductions in mor-
bidity and improved patient outcomes.21,22 Another study 
on older patients transferring from hospital to a long-term 
care facility showed that adding a pharmacist transition 
coordinator on evidence-based medication management and 
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health outcomes could improve the aspects of inappropriate 
use of medications.23
Optimizing prescribing requires appropriate ways to taper 
or withdraw high-risk medications in older adults. Available 
explicit and implicit criteria for appropriate prescribing 
encompass medications that have been validated in, and 
applied to, robust, healthy populations aged 65 and older. 
Therefore, these approaches may not be applicable to the 
more frail and multimorbid oldest old who reside in RACFs.24 
Most attention has been paid to the development of guide-
lines on how to initiate medications, but there are limited 
studies on the most effective way to cease medications.25,26 
Barriers to cease medications include time constraints on 
medical practitioners. This had led some to advocate that 
there should be some systematic approaches to follow in 
ceasing medications.27,28 In responding to polypharmacy 
and minimizing high-risk medications, there appears a need 
for a practical algorithm that helps clinicians identify and 
discontinue potentially inappropriate high-risk medications 
using a systematic approach. This algorithm should signify 
a range of different clinical scenarios in relation to high-risk 
medications and offer an evidence-based approach to identify 
and, if appropriate, discontinue such medications and/or sug-
gesting alternative treatments when required.
Our study has several limitations. Although, combining 
five different explicit criteria gives us an opportunity to 
extract a comprehensive list of high-risk medications, this list 
is not meant to regulate practice in a manner that surpasses the 
clinical judgment and the assessment of a prescriber. Also, 
because of our definition of high-risk medications as a list of 
drugs, the further domains of inappropriate prescribing such 
as underuse of medications and drug–drug interaction might 
be missed. Any adverse health events occurring among the 
residents using high-risk medications were also not inves-
tigated in our study. Considering the small sample size of 
153 patients, the study results may not be representative of 
larger sample size in different nursing home settings.
Conclusion
In this study of 153 residents of four RACFs, we found 
a moderate prevalence of potentially inappropriate high-
risk medications. However, geriatricians made relatively 
few changes, suggesting either that, on balance, prescrip-
tion of these medications was appropriate or, because of 
other factors, there was a reluctance to adjust medications. 
Further research, including a broader survey, is required to 
understand these dynamics. A structured medication review 
using an algorithm for withdrawing medications of high 
disutility might help optimize medication prescribing in 
frail older people.
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